Tovinontrine

Generic Name: Tovinontrine

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆N_₆O_₂

CAS Number: 2062661-53-2

Unique Ingredient Identifier: W248Y1AKOR

Background: Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor. Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease).

Clinical Trials

Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

Phase 2

Recruiting

Conditions: Heart Failure Preserved Ejection Fraction
Cardiovascular Diseases
Heart Diseases
Heart Failure

Interventions: Drug: Tovinontrine (CRD-750
Drug: Placebo

First Posted Date: 2024-01-22

Last Posted Date: 2025-04-16

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 240

Registration Number: NCT06215586

Locations: 🇬🇧
Cardurion Investigative Site, Southampton, United Kingdom
🇩🇪
Cardurion Investigational Site, Dresden, Germany

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

Phase 2

Recruiting

Conditions: Heart Failure
Heart Failure With Reduced Ejection Fraction
Cardiovascular Diseases
Heart Diseases

Interventions: Drug: Tovinontrine (CRD-750)
Drug: Placebo

First Posted Date: 2024-01-22

Last Posted Date: 2025-04-16

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 400

Registration Number: NCT06215911

Locations: 🇬🇧
Cardurion Investigative Site, Southampton, United Kingdom
🇧🇪
Cardurion Investigational Site, Brugge, Belgium
🇬🇪
Cardurion Investigative Site 2, Tbilisi, Georgia

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

Phase 2

Withdrawn

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Other: IMR-687 Placebo
Drug: IMR-687

First Posted Date: 2022-04-05

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Registration Number: NCT05312021

A Study of IMR-687 in Subjects With Sickle Cell Disease

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: IMR-687
Drug: Placebo

First Posted Date: 2020-07-16

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 115

Registration Number: NCT04474314

Locations: 🇬🇧
Guy's and Saint Thomas' NHS Foundation Trust, London, England, United Kingdom
🇬🇧
King's College Hospital NHS Foundation Trust, London, England, United Kingdom
🇺🇬
Uganda Cancer Institute, Kampala, Uganda

and more 46 locations

A Study of IMR-687 in Subjects With Beta Thalassemia

Phase 2

Terminated

Conditions: β Thalassemia

Interventions: Drug: IMR-687
Drug: Placebo

First Posted Date: 2020-06-02

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 122

Registration Number: NCT04411082

Locations: 🇲🇾
Hospital Sultanah Aminah Johor Bharu, Johor Bahru, Johor, Malaysia
🇩🇰
Herlev Hospital, Herlev, Hovedstaden, Denmark
🇫🇷
Hôpital Edouard Herriot, Lyon Cedex 03, Rhone, France

and more 33 locations

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: IMR-687

First Posted Date: 2019-08-13

Last Posted Date: 2022-03-04

Lead Sponsor: Imara, Inc.

Target Recruit Count: 30

Registration Number: NCT04053803

Locations: 🇬🇧
Guy's and St Thomas Hospital CRF, London, United Kingdom
🇬🇧
Royal London Hospital, London, United Kingdom
🇬🇧
Bristol Haematology and Oncology Centre, Bristol, United Kingdom

and more 4 locations

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: IMR-687
Drug: Placebo

First Posted Date: 2018-01-17

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 100

Registration Number: NCT03401112

Locations: 🇺🇸
Loretto Hospital, Chicago, Illinois, United States
🇬🇧
Bristol Haematology and Oncology Centre, Bristol, United Kingdom
🇺🇸
University of Illinois, Chicago, Illinois, United States

and more 10 locations

A Study of IMR-687 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Sickle-Cell; Hb-SC
Sickle Cell Disease
Sickle Beta 0 Thalassemia

Interventions: Drug: IMR-687
Drug: Placebo Oral Capsule

First Posted Date: 2016-12-20

Last Posted Date: 2025-05-15

Lead Sponsor: Cardurion Pharmaceuticals, Inc.

Target Recruit Count: 66

Registration Number: NCT02998450

Locations: 🇺🇸
Quintiles, Overland Park, Kansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy